Zhejiang Conba Pharmaceutical Co (SHSE:600572) Inventories, Finished Goods: ¥647 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600572 Zhejiang Conba Pharmaceutical Co Ltd SHSE:600572
74 GF Score
Price ¥4.50
GF Value ¥5.39
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Zhejiang Conba Pharmaceutical Co Inventories, Finished Goods?

Zhejiang Conba Pharmaceutical Co SHSE:600572 -0.22% 74 Inventories, Finished Goods is ¥647 Mil as of Jun. 2026. GuruFocus rates SHSE:600572 with a GF Score™ of 74/100 and a GF Value™ of ¥5.39 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Zhejiang Conba Pharmaceutical Co's quarterly finished goods declined from Dec. 2025 (¥683 Mil) to Mar. 2026 (¥0 Mil) but then increased from Mar. 2026 (¥0 Mil) to Jun. 2026 (¥647 Mil).

Zhejiang Conba Pharmaceutical Co's annual finished goods increased from Dec. 2023 (¥654 Mil) to Dec. 2024 (¥757 Mil) but then declined from Dec. 2024 (¥757 Mil) to Dec. 2025 (¥683 Mil).

Zhejiang Conba Pharmaceutical Co Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Zhejiang Conba Pharmaceutical Co's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Conba Pharmaceutical Co Inventories, Finished Goods Chart

Zhejiang Conba Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 405.83 557.60 653.62 757.09 682.71

Zhejiang Conba Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 621.66 0.00 682.71 0.00 647.26
SHSE:600572
74GF Score
Zhejiang Conba Pharmaceutical Co Ltd SHSE:600572
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Conba Pharmaceutical Co Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of ¥647 Mil mean?
Zhejiang Conba Pharmaceutical Co (SHSE:600572) has a Inventories, Finished Goods of ¥647 Mil as of Jun. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors.
Is Zhejiang Conba Pharmaceutical Co's Inventories, Finished Goods too high?
Zhejiang Conba Pharmaceutical Co's current Inventories, Finished Goods is ¥647 Mil. Overall, Zhejiang Conba Pharmaceutical Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Conba Pharmaceutical Co's Inventories, Finished Goods compare to ZTS?
Zhejiang Conba Pharmaceutical Co's Inventories, Finished Goods of ¥647 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. Zhejiang Conba Pharmaceutical Co's current Inventories, Finished Goods is ¥647 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Conba Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co (SHSE:600572) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.39, compared to a current price of ¥4.50 — trading 16.5% below its estimated fair value. The current Inventories, Finished Goods is ¥647 Mil. Zhejiang Conba Pharmaceutical Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Zhejiang Conba Pharmaceutical Co (SHSE:600572), the current Inventories, Finished Goods is ¥647 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Conba Pharmaceutical Co (SHSE:600572) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥4.50 is trading 16.5% below its estimated GF Value™ of ¥5.39. GuruFocus considers Zhejiang Conba Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600572:

  • Inventories, Finished Goods: ¥647 Mil
  • GF Value™: ¥5.39 vs. price of ¥4.50 (16.5% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Conba Pharmaceutical Co Business Description

Address No. 568 Binkang Road, New and High-Technology Development Zone, Binjiang District, Zhejiang, Hangzhou, CHN, 310052
Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.
74GF Score

Get the complete analysis for SHSE:600572

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.50
Price
¥5.39
GF Value